Reprint
Neuroproteomics
Edited by
February 2020
318 pages
- ISBN978-3-03928-106-0 (Paperback)
- ISBN978-3-03928-107-7 (PDF)
This book is a reprint of the Special Issue Neuroproteomics that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
The Neuroproteomics Special Issue overviews the unique challenges that must be addressed to carry out meaningful MS/proteomics analyses on neural tissues and the technologies that are available to meet these challenges. The articles on Alzheimer’s disease, addiction, and schizophrenia illustrate how MS/proteomics technologies can be used to improve our ability to diagnose and understand the molecular basis for neurological diseases. Several articles will be of interest to investigators beyond the field of neurological disorders. The review on the discovery of biofluid biomarkers of neurodegenerative dementias will be of interest to investigators searching for other disease biomarkers. Similarly, the review on the role of neuroproteomics in elucidating mechanisms of drug addiction provides an overview of the utility of MS/proteomics approaches for addressing critical questions in addiction neuroscience that should be applicable to investigators involved in virtually any area of biomedical research. Likewise, the article on developing targeted MS approaches for quantifying postsynaptic density proteins will be useful for any investigator who wishes to design targeted assays for virtually any protein. Finally, the peroxidase-mediated proximity labeling technology, described in the article on mapping the proteome of the synaptic cleft, will be of interest to investigators interested in mapping other spatially restricted proteomes.
Format
- Paperback
License
© 2020 by the authors; CC BY-NC-ND license
Keywords
proteomics; basal ganglia; synapses; synapse specificity; neuronal circuits; axons; dendrites; neurodegeneration; synapse; postsynaptic; proteome; mass spectrometry; protein interaction networks; connectome; neurodegeneration; Alzheimer’s disease; cerebrospinal fluid; plasma; serum; proteomics; biomarkers; LC-MS/MS; cocaine; addiction; cytokine; neuroimmune; ventral tegmental area; peptidylglycine α-amidating monooxygenase; cilia; mating; signal peptide; prohormone convertase; carboxypeptidase; matrix metalloproteinase; subtilisin; pherophorin; morphine; opioid receptors; conformational antibody; analgesia; GPCR signaling; phosphorylation; AMPA receptor complex; transmembrane AMPA receptor regulatory protein; synaptic plasticity; adolescence; corticosterone; proteomics; yohimbine; progressive ratio; reinstatement; ethanol; nicotinic receptor; CaMKII; PKA; quantitative phosphoproteomics; mouse; phosphorylation; nicotine; proteomics; proteome; mass spectrometry; Alzheimer’s disease; protein aggregation; laser capture microdissection; splicing; U1 snRNP; synapse; synaptic cleft; trans-synaptic adhesion; proximity labeling; SynCAM; Cadm; Receptor-type tyrosine-protein phosphatase zeta; R-PTP-zeta; Ptprz1; neuroproteome; drug abuse; neuropeptidomics; phosphorylation; interactome; cell type; neuroscience; proteomics; mass spectrometry; neuron; proximity labeling; affinity chromatography; neuroproteomics; biotinylation; amphetamine; spinophilin; protein phosphatase-1; dopamine; striatum; mass spectroscopy; bioinformatics; FGF14; voltage gated channels; schizophrenia; autism; Alzheimer’s Disease; sex-specific differences; synaptic plasticity; cognitive impairment; excitatory/inhibitory tone; n/a; postsynaptic density; PSD; parallel reaction monitoring; PRM; targeted proteomics; data-independent acquisition; DIA; quantitative mass spectrometry; n/a